On June 3, 2025 Stada, a leading healthcare company in Consumer Healthcare, Generics and Specialty pharmaceuticals, achieved record earnings on revenues growth in its financial first quarter ended 31 March 2025 (Press release, Stada, JUN 3, 2025, View Source [SID1234654337]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Group adjusted, constant-currency (cc) revenues advanced by 4% on an organic basis to €1.081 billion. This development was driven by a double-digit increase in revenues by the Group’s Specialty segment, aided by further market penetration with the Uzpruvo (ustekinumab) biosimilar launched in Europe from July 2024.

Adjusted cc earnings before interest, tax, depreciation and amortization (EBITDA) improved by 5% to €245 million, a historic high against a strong prior-year base.

"Our resilient business model delivered again in the first quarter of this year, as our diversified portfolio and broad footprint enabled us to overcome geopolitical challenges and market uncertainty," commented STADA’s CEO, Peter Goldschmidt. "Our symbiotic threesegment strategy gives us a broad basis for growth, with no dependence on individual products or countries."